Impax Laboratories Inc (NASDAQ:IPXL)

45.74
Delayed Data
As of Mar 27
 +0.87 / +1.94%
Today’s Change
22.12
Today|||52-Week Range
47.70
+44.38%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$3.3B

Company Description

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture and marketing of controlled-release and niche generics. It operates through two divisions: Global Pharmaceuticals and Impax Pharmaceuticals. The Global Pharmaceuticals Division concentrates its efforts on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products. The Impax Pharmaceuticals Division focuses on the development of proprietary brand pharmaceutical products addressing central nervous system disorders. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.

Contact Information

Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward California 94544-7003
P:(510) 240-6000
Investor Relations:
(215) 558-4526

Employees

Shareholders

Mutual fund holders52.39%
Other institutional39.32%
Individual stakeholders13.43%

Top Executives

George Frederick WilkinsonPresident, Chief Executive Officer & Director
Bryan M. ReasonsChief Financial Officer & Senior Vice President
Jeffrey D. NornholdSenior Vice President-Technical Operations
Mark A. SchlossbergSecretary, Senior Vice President & General Counsel
Michael J. NestorPresident-Impax Pharmaceuticals Division

To view my watchlist

Not a member yet?

Sign up now for a free account